相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization
Kevin Outterson et al.
TRANSLATIONAL RESEARCH (2020)
Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study
Jeffrey R. Strich et al.
LANCET INFECTIOUS DISEASES (2020)
It's worse than we thought: the US market for novel Gram-negative antibiotics
Cornelius J Clancy et al.
LANCET INFECTIOUS DISEASES (2020)
Designing development programs for non-traditional antibacterial agents
John H. Rex et al.
NATURE COMMUNICATIONS (2019)
A shot in the arm for new antibiotics
Kevin Outterson
NATURE BIOTECHNOLOGY (2019)
Introduction and geographic availability of new antibiotics approved between 1999 and 2014
Cecilia Kallberg et al.
PLOS ONE (2018)
Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance
Christine Ardal et al.
CLINICAL INFECTIOUS DISEASES (2017)
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach
John H. Rex et al.
LANCET INFECTIOUS DISEASES (2016)
Delays in the submission of new drugs in Canada
Ali Shajarizadeh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2015)
The 10 x '20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
David N. Gilbert et al.
CLINICAL INFECTIOUS DISEASES (2010)
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations
K. Tsuji et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2010)
分享论文
